

Financial Results for FY2025 Third Quarter (April 1, 2025 – December 31, 2025)

February 3, 2026



(Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

1. Consolidated Financial Results for FY2025 Third Quarter

Summary for Q3 FY2025	4
Consolidated Financial Results Summary	5
Sales Revenue by Reporting Segment	6
Core Operating Income by Reporting Segment	7
Core Operating Income Analysis by Reporting Segment	8
Consolidated Statement of Financial Position	13
Consolidated Statement of Cash Flows	14

2. Outlook for FY2025

FY2025 Outlook for the Business Environment	16
Summary of Financial Forecast for FY2025	17
Performance Forecast for FY2025	18
Sales Revenue and Core Operating Income by Reporting Segment	19

(Reference)

Sales Revenue by Reporting Segment (Quarterly)	21
Core Operating Income by Reporting Segment (Quarterly)	22
Sales Revenue Analysis by Reporting Segment	23
Major Group Companies	26
Crop Protection Product Sales by Region	27

1. Consolidated Financial Results for FY2025 Third Quarter

Summary for Q3 FY2025

4

Core Operating Income

(Billions of yen)		
Q3 FY2024	Q3 FY2025	FY2025 Forecast (ann. in Nov.)
60.1	186.8	185.0

Substantial gain on sale of businesses※
(Approx. 10.0) (Approx. 80.0) (Approx. 80.0)

※Excluding impact of the timing difference in the partial shares in Petro Rabigh

Net Income Attributable to Owners of the Parent

(Billions of yen)		
Q3 FY2024	Q3 FY2025	FY2025 Forecast (ann. in Nov.)
28.6	87.4	45.0

● **Core operating income and net income attributable to owners of the parent significantly increased from the prior year, and exceeded the FY2025 forecast.**

● Core operating income was **driven by Sumitomo Pharma** (strong sales of products and gain on the divestiture of the Asian business), **Essential & Green Materials** (gain on the partial sale of shares in Petro Rabigh and better trade terms), and **Agro & Life Solutions** (solid performance of the crop protection chemical business).

● In net income attributable to owners of the parent, we anticipate that the **recording of losses from non-recurring items will be concentrated in the fourth quarter**. Due to this, in the third quarter, net income attributable to owners of the parent exceeded the FY2025 forecast.

Consolidated Financial Results Summary

				(Billions of yen)
	Q3 FY2025	Q3 FY2024	Variance	Variance Ratio
Sales revenue	1,706.3	1,904.8	(198.5)	(10.4)%
Core operating income	186.8	60.1	126.8	211.1%
of which equity-method investments	(43.2)	(53.3)	10.1	-
Total non-recurring items (breakdown below)	(6.4)	85.4	(91.8)	-
Restructuring costs	(5.9)	(14.8)	9.0	-
Impairment losses	(3.9)	(5.5)	1.6	-
Gains on sales of property, plant and equipment, and intangible assets	1.1	11.5	(10.3)	-
Share of profit of investments accounted for using the equity method (non-recurring factors)	-	86.0	(86.0)	-
Gains on fair value measurement of the residual interest	-	9.4	(9.4)	-
Others	2.2	(1.2)	3.4	-
Operating income	180.4	145.4	35.0	24.1%
Finance income/expenses (breakdown below)	(36.0)	(105.4)	69.3	-
Gain (loss) on foreign currency transactions including gain (loss) on derivatives	(7.7)	15.0	(22.8)	-
Loss on valuation of investment securities	(13.6)	-	(13.6)	-
Loss on debt waiver for a loan	-	(109.8)	109.8	-
Others	(14.7)	(10.6)	(4.1)	-
Income before taxes	144.4	40.1	104.3	260.4%
Income tax expenses	(0.3)	0.6	(0.9)	-
Net income	144.1	40.7	103.5	254.2%
Net (income) loss attributable to non-controlling interests	(56.8)	(12.1)	(44.7)	-
Net income attributable to owners of the parent	87.4	28.6	58.8	205.7%
ROE	9.0%	3.0%		
Exchange rate (yen/\$)	148.71	152.64		
Naphtha price (yen/kl)	65,000	76,400		
Overseas sales revenue ratio	71.2%	69.8%		


Sales Revenue by Reporting Segment

6

	Q3 FY2025	Q3 FY2024	Variance	Ratio	Sales price variance	Shipping volume variance	Foreign currency conversion variance
Agro & Life Solutions	346.9	363.1	(16.2)	(4.5)%	(1.5)	(8.4)	(6.3)
ICT & Mobility Solutions	431.8	461.2	(29.4)	(6.4)%	(10.0)	(8.8)	(10.6)
Advanced Medical Solutions	35.6	40.7	(5.1)	(12.5)%	0.0	(5.2)	0.1
Essential & Green Materials	511.0	672.9	(161.9)	(24.1)%	(37.5)	(120.9)	(3.6)
Sumitomo Pharma *	346.4	292.8	53.6	18.3%	(0.5)	61.7	(7.6)
Others	34.6	74.1	(39.4)	(53.2)%	0.0	(39.4)	(0.0)
Total	1,706.3	1,904.8	(198.5)	(10.4)%	(49.5)	(121.0)	(28.0)

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Due to this, sales revenue differs between this segment and Sumitomo Pharma, Co., Ltd.

Variance analysis




Core Operating Income by Reporting Segment

7

	Q3 FY2025	Q3 FY2024	Variance	Price variance	Cost variance	Shipping volume variance and other	(Billions of yen)
Agro & Life Solutions	28.1	19.5	8.6	2.5	(2.0)	8.1	
ICT & Mobility Solutions	46.5	59.7	(13.2)	(8.5)	(1.0)	(3.7)	
Advanced Medical Solutions	0.3	1.2	(0.9)	0.0	(0.5)	(0.4)	
Essential & Green Materials	19.8	(44.3)	64.1	12.5	(1.0)	52.6	
Sumitomo Pharma *	111.2	24.4	86.9	(0.5)	8.0	79.4	
Others & Adjustments	(19.1)	(0.4)	(18.7)	0.0	0.0	(18.7)	
Total	186.8	60.1	126.8	6.0	3.5	117.3	

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Due to this, core operating income differs between this segment and Sumitomo Pharma, Co., Ltd.

Variance analysis




Core Operating Income Analysis by Reporting Segment

8

Agro & Life Solutions

Total ¥ 28.1 billion ¥ 8.6 billion from Q3 FY2024




Price variance	Crop Protection	Improved trade terms for overseas crop protection products
Volume and other variances	Crop Protection	Strong shipments in Japan, India, and other regions Lower income from exports due to stronger yen Stronger yen's effect on the sales of subsidiaries outside Japan when converted into yen

Core Operating Income Analysis by Reporting Segment

9

ICT & Mobility Solutions

Total ¥ 46.5 billion ¥ (13.2) billion from Q3 FY2024




Price variance	Displays	Decline in the selling price of display-related materials
Volume and other variances	Displays	Decrease in shipments of display-related materials
	Semiconductors	Gain on the sale of the large LCD polarizing film business
	Displays Semiconductors	Market conditions continue to slowly recover, and shipments have increased
	Displays Semiconductors	Lower income from exports due to stronger yen Stronger yen's impact on the sales of subsidiaries outside Japan when converted into yen

Core Operating Income Analysis by Reporting Segment

10

Advanced Medical Solutions

Total ¥ 0.3 billion ¥ (0.9) billion from Q3 FY2024




**Volume
and other
variances**

Decrease in sales at affiliated companies

Essential & Green Materials

Total ¥ 19.8 billion ¥ 64.1 billion from Q3 FY2024




Price variance	Profit margins improved in synthetic resins and alumina
Volume and other variances	Gain on partial sale of shares in Petro Rabigh Improvement in profitability in investments accounted for using the equity method, due to Petro Rabigh's improved refining margins

Core Operating Income Analysis by Reporting Segment

12

Sumitomo Pharma

Total ¥ 111.2 billion ¥ 86.9 billion from Q3 FY2024



Price variance	NHI drug price revisions in Japan
Cost variance	Lower fixed costs
Volume and other variances	Gain posted on the partial divestiture of the Asian business Increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (treatment for overactive bladder)

Consolidated Statement of Financial Position

13

(Billions of yen)

	31-Dec-25	31-Mar-25	Variance		31-Dec-25	31-Mar-25	Variance
Current assets	1,600.8	1,583.1	17.7	Liabilities	2,244.3	2,365.4	(121.1)
Cash and cash equivalents	214.8	209.8	4.9	Trade and other payables	473.6	488.1	(14.5)
Trade and other receivables	604.6	593.8	10.8	Interest-bearing liabilities	1,221.5	1,286.1	(64.6)
Inventories	661.4	625.2	36.2	Others	549.2	591.1	(41.9)
Others	120.0	154.2	(34.2)	Equity	1,266.2	1,074.4	191.7
Non-current assets	1,909.6	1,856.7	53.0	Shareholders' equity	779.7	722.3	57.4
Property, plant and equipment	773.4	759.3	14.1	Other components of equity	250.2	178.5	71.7
Goodwill and intangible assets	498.4	497.1	1.2	Non-controlling interests	236.2	173.6	62.6
Others	637.9	600.3	37.6	Total	3,510.4	3,439.8	70.6
Total	3,510.4	3,439.8	70.6	Ratio of equity attributable to owners of the parent to total assets	29.3%	26.2%	3.2%
				D/E ratio (times)	0.96	1.20	(0.23)

Consolidated Statement of Cash Flows

14

(Billions of yen)

	Q3 FY2025	Q3 FY2024	Variance	FY2024
Cash flows from operating activities	111.6	140.7	(29.1)	233.0
Cash flows from investing activities	(39.8)	56.7	(96.6)	85.2
Free cash flows	71.8	197.5	(125.7)	318.3
Cash flows from financing activities	(100.6)	(141.7)	41.1	(300.8)
Others	11.5	(2.5)	14.0	(6.8)
Increase (decrease) in cash and cash equivalents	(17.3)	53.2	(70.5)	10.7
Cash and cash equivalents at the end of the period	214.8	258.3	(43.5)	209.8

2. Outlook for FY2025

Economic Conditions

- Although investments in the field of technology are firmly supporting the global economy, future prospects remain uncertain due to the expansion of protectionism and increased geopolitical risks.

Business Environment

Prev.

Revised

Crop Protection



The price competition will continue, and inventory congestion in the distribution chain remains varied by region.

Methionine



Although the methionine market recovered in the first half of FY2025, it will continue to decline in the second half of the fiscal year.

Displays



Steady growth in mobile device-related components remains.

Semiconductors




Although there will continue to be variances in demand for silicon semiconductors across different fields, overall demand will be solid.

Petrochemicals/ Raw Materials



The petrochemical market will continue to have low margins.

Forecast for FY2025



Core operating income: projected to be 200.0 billion yen, an upward revision from 185.0 billion yen

Net income attributable to owners of the parent: projected to reach 55.0 billion yen, an upward revision from 45.0 billion yen

Year-end dividend: projected at 7.5 yen, an upward revision from 6 yen

- Core operating income is improving over time
- Profit from business activities is forecasted to significantly improve to 120 billion yen in FY2025, from approximately 80 billion yen in FY2024
- Fundamental structural reforms have led to significant improvements in **Sumitomo Pharma and Essential & Green Materials**
- Annual dividend has been revised upward to 13.5 yen (9 yen in FY2024)

※ Excluding impact of the timing difference in the partial sale of shares in Petro Rabigh

Performance Forecast for FY2025

18

(Billions of yen)

	FY2025 forecast	FY2025 forecast (announced in Nov.)	Variance	Variance ratio	FY2024
Sales revenue	2,300.0	2,290.0	10.0	0.4%	2,606.3
Core operating income	200.0	185.0	15.0	8.1%	140.5
Net income attributable to owners of the parent	55.0	45.0	10.0	22.2%	38.6
ROE	5.8%	4.9%			4.1%
Exchange rate (yen/\$)	149.03 (Jan-Mar 150.00)	145.51 (2nd Half 145.00)			152.62
Naphtha price (yen/kl)	64,600 (Jan-Mar 63,500)	64,200 (2nd Half 63,500)			75,600
Cash dividends (yen)	Interim dividend	6.00	6.00		3.00
	Year-end dividend	7.50	6.00		6.00
	Annual dividend	13.50	12.00		9.00

Sales Revenue and Core Operating Income by Reporting Segment

19

(Billions of yen)

		FY2025 forecast	FY2025 forecast (announced in Nov.)	Variance	FY2024
Agro & Life Solutions	Sales Revenue	530.0	530.0	-	540.2
	Core Operating Income	55.0	55.0	-	55.0
ICT & Mobility Solutions	Sales Revenue	560.0	550.0	10.0	607.0
	Core Operating Income	55.0	53.0	2.0	70.6
Advanced Medical Solutions	Sales Revenue	60.0	60.0	-	62.1
	Core Operating Income	4.0	4.0	-	4.0
Essential & Green Materials	Sales Revenue	680.0	680.0	-	899.0
	Core Operating Income	13.0	13.0	-	(58.5)
Sumitomo Pharma	Sales Revenue	420.0	420.0	-	398.0
	Core Operating Income	100.0	100.0	-	35.3
Others	Sales Revenue	50.0	50.0	-	99.9
	Core Operating Income	(27.0)	(40.0)	13.0	34.2
Total	Sales Revenue	2,300.0	2,290.0	10.0	2,606.3
	Core Operating Income	200.0	185.0	15.0	140.5
	Of which actual gains on sale of businesses※	approx. 80.0	approx. 80.0		

※Excluding impact of the timing difference in the partial shares in Petro Rabigh

(Reference)

Sales Revenue by Reporting Segment (Quarterly)

21

(Billions of yen)

	FY2024				FY2025					Total Forecast
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4 (Forecast)		
Agro & Life Solutions	106.4	118.6	138.1	177.1	96.9	116.1	133.9	183.1	530.0	
ICT & Mobility Solutions	152.7	154.8	153.8	145.8	137.4	146.1	148.3	128.2	560.0	
Advanced Medical Solutions	13.2	13.6	14.0	21.4	9.1	12.1	14.5	24.4	60.0	
Essential & Green Materials	225.0	226.0	222.0	226.1	165.4	163.8	181.8	169.0	680.0	
Sumitomo Pharma	90.6	89.8	112.4	105.2	107.4	118.7	120.3	73.6	420.0	
Others	24.3	26.5	23.2	25.8	10.0	12.6	12.1	15.4	50.0	
Total	612.1	629.3	663.4	701.4	526.1	569.3	610.9	593.7	2,300.0	

Core Operating Income by Reporting Segment (Quarterly)

22

(Billions of yen)

	FY2024				FY2025					Total Forecast
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4 (Forecast)		
Agro & Life Solutions	4.9	9.2	5.4	35.5	2.2	9.0	16.9	26.9	55.0	
ICT & Mobility Solutions	21.2	22.4	16.1	10.8	18.4	14.7	13.4	8.5	55.0	
Advanced Medical Solutions	0.5	(0.1)	0.8	2.8	(1.0)	(0.4)	1.7	3.7	4.0	
Essential & Green Materials	(19.6)	(15.2)	(9.6)	(14.1)	(5.5)	(13.1)	38.4	(6.8)	13.0	
Sumitomo Pharma	0.9	2.1	21.4	10.9	21.0	76.3	13.9	(11.2)	100.0	
Others & Adjustments	(2.2)	5.3	(3.6)	34.6	(7.4)	(5.5)	(6.2)	(7.9)	(27.0)	
Total	5.7	23.8	30.6	80.5	27.7	81.0	78.1	13.2	200.0	

Sales Revenue Analysis by Reporting Segment

23

Agro & Life Solutions



Total ¥ 346.9 billion

¥ (16.2) billion from Q3 FY2024

Price

(1.5)

Volume

(8.4)

□ Decrease in shipments of methionine

Foreign exchange

(6.3)

ICT & Mobility Solutions



Total ¥ 431.8 billion

¥ (29.4) billion from Q3 FY2024

Price

(10.0)

□ Decline in the selling prices of display-related materials

Volume

(8.8)

□ Decrease in shipments of display-related materials

Foreign exchange


(10.6)

□ Recovery in demand for processing materials for semiconductors

Sales Revenue Analysis by Reporting Segment

24

Advanced Medical Solutions



Total ¥ 35.6 billion

¥ (5.1) billion from Q3 FY2024

Price

0.0

Volume


(5.2)

Foreign exchange

0.1

- Decrease in orders for affiliated company business
- Increase in shipments for oligonucleotide business

Essential & Green Materials



Total ¥ 511.0 billion

¥ (161.9) billion from Q3 FY2024

Price

(37.5)

Volume

(120.9)


Foreign exchange

(3.6)

- Decline in market prices for naphtha and products
- Exit from the aluminum business etc.
- Decrease in shipments from sales subsidiaries due to periodic shutdown maintenance at Petro Rabigh

Sales Revenue Analysis by Reporting Segment

25



Company	Sales Revenue		Profit
	Q3 FY2025	Q3 FY2024	
The Polyolefin Company (Singapore) (Millions of USD)	560	645	↗ Improvement in profit margin
PCS (Millions of USD)	1,637	1,820	↘ Deterioration in profit margins
Rabigh Refining and Petrochemical Company (Millions of SAR)	24,356	27,952	↗ Improvement in petroleum refining margins
Dongwoo Fine-Chem (Billions of KRW)	1,563.4	1,569.0	↘ Decrease in sales volume of display-related materials and deterioration in profit margins
Sumitomo Chemical Brasil Indústria Química S.A. (Millions of BRL)	2,679	2,983	↗ Market conditions improved
Valent North America and subsidiaries (Millions of USD)	597	599	↗ Market conditions improved

※Valent North America has changed its company name to Sumitomo Biorational Company.

Crop Protection Product Sales by Region

27

(Billions of yen)

	Q3 FY2025	Q3 FY2024	Variance	Reasons for Change
Japan	53.1	44.9	8.2	<ul style="list-style-type: none"> • Increase in shipments through moving up the sales period, etc.
North America	52.4	55.0	(2.6)	
Central & South America	83.4	94.7	(11.3)	<ul style="list-style-type: none"> • Foreign currency conversion variance (JPY strengthening against the BRL) • Decline in shipments due to unfavorable weather conditions, etc.
Asia (including India)	50.9	51.3	(0.4)	
Europe & Others	25.8	19.4	6.4	<ul style="list-style-type: none"> • Foreign currency conversion variance (JPY weakening against the EUR) • Increase in shipments through moving up the sales period, etc.
Total	265.6	265.3	0.3	